- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Dr. Phillip Barnes BSc, PhD, BMBCh
Independent Director
Dr. Barnes holds a B.S. in Basic Medical Sciences with Anatomy, and Ph.D. in Anatomy and Neuroendocrinology from the University of London and a clinical medical degree (B.M. B.Ch.) from the University of Oxford. Dr. Barnes is currently retired. Between 2009 and 2016, Dr. Barnes served as Executive Medical Director and Senior Manager on a number of United Kingdom Department of Health, National Health Service, or NHS, hospital and Foundation Trust Boards. Between 2000 and 2009, Dr. Barnes was also involved in a number of national and regional advisory groups for the NHS and pharmaceutical industry. Dr. Barnes was Consultant Neurologist at King’s College Hospital, London, from 1995 to 2009 and Hon. Senior Lecturer in Neurology at King’s College London from 1999 to 2009. From 1995 to 1998, Dr. Barnes served as Clinical Director for Neurology, a managerial and administrative role and from 1998 until 2008 as Director of the King’s Neurosciences Centre, the United Kingdom’s largest Regional Neuroscience Centre. Our board of directors believes that Dr. Barnes is qualified to serve as a director of the Company based on his extensive experience both as a clinician and senior manager within the United Kingdom’s NHS and related academic institutions.